STOCK TITAN

Sensus Healthcare Inc Stock Price, News & Analysis

SRTS Nasdaq

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.

Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.

Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.

Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.

Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) announces participation in the upcoming Fall Clinical Dermatology Conference from October 21-24, 2021, in Las Vegas. Over 1,200 physicians are registered to attend this first major in-person dermatology event in 18 months. Key opinion leaders will present on superficial radiation therapy (SRT) for non-melanoma skin cancer. CEO Joe Sardano emphasizes strong sales momentum for the second half of 2021, driven by favorable reimbursement changes and a backlog of orders. Sensus anticipates achieving profitability this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
none
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), based in Boca Raton, Fla., will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13 to 15, 2021. CEO Joe Sardano's presentation will be accessible via a webcast starting at 7:00 am (EST) on September 13. Sensus Healthcare specializes in non-invasive treatments for both oncological and non-oncological conditions, featuring technologies like the Sculptura™ and SRT-100™ systems, aimed at enhancing patient quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
conferences
-
Rhea-AI Summary

Sensus Healthcare (SRTS) reported Q2 2021 revenues of $5.4 million, a 358% increase year-over-year and 77% sequentially. The net loss narrowed to $(0.3) million or $(0.02) per share, improving from $(2.6) million or $(0.16) per share in Q2 2020. The company shipped 17 systems, enhancing its installed base to 515 systems. Cash stood at $15.2 million with no long-term debt. Management expressed optimism for continued growth, aided by new reimbursement schedules and an expanded international strategy, particularly in China and India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
-
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 5, 2021, at 4:30 p.m. Eastern to discuss its Q2 2021 financial results and provide business updates. The call will be accessible via dial-in numbers and a live webcast. Sensus is focused on non-invasive medical treatments for various conditions, including its Sculptura™ and SRT systems for cancer treatment and skin conditions. This call aims to communicate recent achievements and future milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS), a leader in non-invasive medical devices, announced management's participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. The conference will facilitate one-on-one virtual meetings with investors. Sensus specializes in innovative treatments for oncological and non-oncological conditions, including the Sculptura™ system for radiation therapy and SRT-100™ for treating skin cancers. The company's focus is on enhancing patient quality of life through advanced technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
-
Rhea-AI Summary

Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
-
Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its Q1 2021 financial results and provide a business update. The call will be accessible via dial-in numbers (888-390-3967 for U.S. and Canada; 862-298-0702 for international) and a live webcast. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions, including the Sculptura™ system and SRT-100™ technology for skin cancer treatments, emphasizing innovation in patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $3.39 as of August 29, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 52.3M.
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

52.28M
13.65M
16.98%
28.46%
5.02%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON